A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Dupilumab (Primary) ; Mometasone
- Indications Nasal polyps
- Focus Therapeutic Use
- Acronyms SINUS-52
- Sponsors Sanofi
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2017 Planned End Date changed from 1 Dec 2018 to 19 Nov 2018.
- 18 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 19 Nov 2018.